首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OGP |
| Uniprot No | Q12889 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-678aa |
| 氨基酸序列 | MWKLLLWVGLVLVLKHHDGAAHKLVCYFTNWAHSRPGPASILPHDLDPFLCTHLIFAFASMNNNQIVAKDLQDEKILYPEFNKLKERNRELKTLLSIGGWNFGTSRFTTMLSTFANREKFIASVISLLRTHDFDGLDLFFLYPGLRGSPMHDRWTFLFLIEELLFAFRKEALLTMRPRLLLSAAVSGVPHIVQTSYDVRFLGRLLDFINVLSYDLHGSWERFTGHNSPLFSLPEDPKSSAYAMNYWRKLGAPSEKLIMGIPTYGRTFRLLKASKNGLQARAIGPASPGKYTKQEGFLAYFEICSFVWGAKKHWIDYQYVPYANKGKEWVGYDNAISFSYKAWFIRREHFGGAMVWTLDMDDVRGTFCGTGPFPLVYVLNDILVRAEFSSTSLPQFWLSSAVNSSSTDPERLAVTTAWTTDSKILPPGGEAGVTEIHGKCENMTITPRGTTVTPTKETVSLGKHTVALGEKTEITGAMTMTSVGHQSMTPGEKALTPVGHQSVTTGQKTLTSVGYQSVTPGEKTLTPVGHQSVTPVSHQSVSPGGTTMTPVHFQTETLRQNTVAPRRKAVAREKVTVPSRNISVTPEGQTMPLRGENLTSEVGTHPRMGNLGLQMEAENRMMLSSSPVIQLPEQTPLAFDNRFVPIYGNHSSVNSVTPQTSPLSLKKEIPENSAVDEEA |
| 预测分子量 | 75,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OGP(成骨生长肽)重组蛋白的3篇示例参考文献(注：以下文献为示例，非真实存在)：
1. **文献名称**: *Recombinant OGP Enhances Bone Regeneration in Rat Calvarial Defects*
**作者**: Smith J, et al.
**摘要**: 本研究通过在大鼠颅骨缺损模型中注射重组OGP蛋白，证明其显著促进新骨形成。组织学分析显示OGP组血管生成和成骨细胞活性较对照组提高2倍，表明其在骨组织工程中的治疗潜力。
2. **文献名称**: *Mechanistic Insights into Recombinant OGP-Stimulated Osteoblast Differentiation*
**作者**: Chen L, Wang H.
**摘要**: 文章通过体外实验揭示重组OGP通过激活MAPK/ERK信号通路诱导间充质干细胞向成骨细胞分化。蛋白质组学数据进一步证实OGP上调了Runx2和骨钙素表达，为靶向骨疾病治疗提供理论依据。
3. **文献名称**: *Optimization of Recombinant OGP Production Using E. coli Expression System*
**作者**: Kim S, et al.
**摘要**: 该研究优化了大肠杆菌表达系统生产重组OGP的工艺，通过密码子优化和温度调控使产量提升至120 mg/L。纯化后的蛋白经质谱验证具有与天然OGP相同的生物活性，为规模化制备奠定基础。
(提示：如需真实文献，建议在PubMed/Google Scholar以“recombinant osteogenic growth peptide”为关键词检索最新研究。)
**Background of OGP Recombinant Protein**
Osteogenic Growth Peptide (OGP), a naturally occurring 14-amino-acid polypeptide, was initially isolated from bone marrow and blood in the 1990s. It plays a critical role in bone metabolism and regeneration by promoting osteoblast proliferation, differentiation, and mineralization. OGP is derived from the C-terminal region of histone H4. though its biological activity is distinct from histone-related functions.
Recombinant OGP is produced using genetic engineering techniques, typically expressed in *E. coli* or yeast systems, to ensure high purity and scalability. This approach overcomes limitations of natural extraction, such as low yield and contamination risks. The recombinant form retains the native peptide’s bioactivity, including its ability to bind to specific cell surface receptors (e.g., Gi-protein-coupled receptors) and activate intracellular signaling pathways like MAPK and PI3K/Akt, which regulate bone formation and repair.
Research highlights OGP’s therapeutic potential in treating bone-related disorders, such as osteoporosis, fractures, and periodontal defects. It also exhibits systemic effects, including hematopoiesis stimulation and immune modulation. Recent studies explore its applications beyond orthopedics, such as neuroprotection and wound healing. However, challenges like short plasma half-life and delivery optimization remain active areas of investigation.
Overall, OGP recombinant protein represents a promising candidate for regenerative medicine, combining natural osteogenic properties with the advantages of biotechnological production. Ongoing studies aim to refine its clinical translation through structural modifications or carrier systems to enhance stability and efficacy.
×
